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Abstract
Background: Endothelial Progenitor Cell (EPC) is the progenitor of endothelial cell which has important role in  regulation 
of vascular wall integrity and homeostasis, to protect vessels from inflamation and thrombosis, that leads into pathogenesis 
of coronary artery disease. Growth factors proven has important role to stimulate transduction signal in the process of 
proliferation of EPC. Platelet Rich Plasma (PRP) contains variety of growth factors, wellknown role in homeostasis and 
wound healing process. Therefore, this study was conducted to analyze the effect of PRP on proliferation of EPC of 
Stable Coronary Artery Disease (SCAD) patient. To analyze the effect of Platelet Rich Plasma (PRP) on the proliferation of 
Endothelial Progenitor Cell (EPC) from peripheral blood of patient with SCAD    
Methods: This is an in vitro, true experimental, post-test only control group design. The mononuclear cells were isolated 
from peripheral blood of SCAD patient and cultured in M-199 medium. EPC divided into 3 groups, which received Platelet 
Rich Plasma (PRP), Platelet Poor Plasma (PPP), and control. After 14 days of incubation, immunocytochemical examination 
was performed, EPC which marked with CD34, FITC labeled,was counted using immunofluoroscence microscope. Data 
analysis using ANOVA test.
Results: Cell counting showed significant increase of EPC proliferation in PRP group compared to PPP group (1.052 ± 
0.16 vs 0.762 ± 0.19, p = 0.003), and control group as well (1.052 ± 0.16 vs 0.068 ± 0.05, p = <0.001). EPC proliferation 
in PPP group also increase significantly compared to control group (0.762 ± 0.19 vs 0.068 ± 0.05, p = <0.001).
Conclusion : Platelet Rich Plasma (PRP) increase EPC proliferation significantly from peripheral blood of SCAD patient.
(Indonesian J Cardiol. 2019;40:258-261)
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Introduction
Coronary artery disease (CAD) has high prevalence for morbidity and mortality rate worldwide. Current therapies for this cardiovascular diseases (CVD) include 
lifestyle management, pharmacological control for 
risk factors and revascularization, have improved 
the survival but not completely control the disease, 
doi: 10.30701/ijc.v40i2.851
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therefore new approaches like cell-based therapy are 
needed1. Endothelial cell dysfunction is condition that 
lead to pathologic atherosclerotic in CAD patients. 
An increasing evidence suggest that cardiovascular risk 
factors affect the number and properties of EPC, the 
inverse correlation is found between both2.  In 1997, 
Asahara and his colleagues first isolated mononuclear 
cell (MNC) that express CD34 and VEFG-2 from 
human peripheral blood, named Endothelial Progenitor 
Cell (EPC)3 . This cells play an important role in 
the recovery and repair of injured endothelium by 
counteracting the detrimental CVD risks factor 
induced damages. Growth factors has proven role in 
stimulating transduction signal for proliferation of EPC 
and promote neovascularization4. Platelet Rich Plasma 
(PRP) which has minimum  5 times higher of platelets 
compared to baseline values for whole blood, has been 
used clinically in humans since 1970s for its healing 
properties attributed of autologous growth factors (GF) 
that may enhance the healing process on a cellular 
level5. Platelet also contains the angiogenic GF that 
believed promote the neovascularization process. So in 
this research, we woud like to know the effect of PRP 
on proliferation of EPC in  peripheral blood of stable 
coronary artery disease (SCAD).
Methods
Blood samples were taken from patients with SCAD 
which are man, had narrowing of ≥50% in the left 
main coronary artery and ≥70% in one or several of 
the major coronary arteries from angiography. Patients 
with history of acute myocardial infarction, acute limb 
ischemia, or after  revascularization therapy include stent 
placement or coronary artery bypass grafting (CABG) 
were excluded. 
 Written informed consent was obtained from 
patients before peripheral blood drawing. The protocol 
was approved by local ethics committee (0421/KEPK/
VII/2018).
Preparation of PRP and Platelet Poor Plasma 
(PPP)
Peripheral blood (20 mL) was collected from SCAD 
patient using anticoagulant, citrate-phosphatedextrose 
solution. Collected blood was centrifuged at 2400 rpm 
for 10 minutes at 200C and the supernatant (plasma) 
including the buffy coat and 0.5 mL below buffy coat 
was decanted to the other tube and red blood cells 
(RBCs) and white blood cells (WBCs) were discarded. 
Secondary centrifugation was performed at 3600 rpm 
for 10 minutes at 200C. The clear supernatant (plasma) 
was decanted off until 0.5 mL was left and the middle 
portion of supernatant (plasma) was taken as PPP. 
Finally, remaining supernatant including buffy coat and 
0.5 mL below buffy coat was taken as PRP 6.
Isolation and culture of EPCs 
Peripheral blood from SCAD patient (40 ml) 
was diluted with phosphate buffered saline (PBS) 
containing 2% of fetal bovine serum (FBS). It was then 
centrifuged on Ficoll-Histopaque density gradients and 
interface mononuclear cells (MNCs) were collected. 
After two washes in PBS containing 2% of FBS, pellet 
were taken and cells counted using hemocytometry. 
Each 5x106cells/ml mononuclear diluted with 
M-199 stemcell expansion medium were plated on 
24-fibronectin coated well plates cells, divided in to 3 
groups with different treat (PRP 20%, PPP 20% ,and 
Control). Every group also given  antibiotics  (Penicillin 
and Streptomycin). Cells then incubated for 14 days at 
37 0C and 5% of CO2.
Immunofluorescence assay 
Adherent cells were taken and washed with PBS and 
fixed with 3% formaldehyde for 15 minutes. Cells were 
stained with a FITC anti-CD34 antibody. Expression of 
the cells was documented with fluorescence microscope. 
Statistical analysis 
Data in normal distribution were reported as mean±SD. 
To analyse differences for normally distributed data, 
one-way ANOVA was used. Differences were considered 
significant if p-values were <0.05. All statistical analyses 
were performed with SPSS for Windows (IBM Corp., 
Armonk, NY).
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Results
PRP increase the proliferation of EPC 
In this study, Endothelial Progenitor Cells (EPC) 
which positive stained by CD34+ and checked by 
immunofluoroscence microscope (Figure 1), compared 
among goups treated with PRP, PPP, and control. The 
result showed significant increase in group treated with 
PRP compared to PPP in (1.052 ± 0.16 vs 0.762 ± 
0.19, p = 0.003) and significant increase compared to 
control group as well (1.052 ± 0.16 vs 0.068 ± 0.05, 
p = <0.001). EPC proliferation in PPP group also 
significantly increase compared to control group (0.762 
± 0.19 vs 0.068 ± 0.05, p = <0.001).
 
Figure 1. Immunofluorescence expression of CD34
Discussion
The result of the study showed that PRP increase 
the proliferation of EPC significantly compared to 
PPP and control group. It has been recognized that 
plateletes in PRP secreted various growth factors 
during the degranulation. Different growth factors 
in PRP, including vascular endothelial growth factors 
(VEGF), platelet-derived growth factors (PDGF), 
epitelial growth factors( EGF), and transforming 
growth factor beta 1 (TGF-β1),  have different role in 
angiogenesis and restoration of blood flow following 
ischemia. VEGF is the principal stimulatory factor of 
angiogenesis after ischemia 7.  VEGF causes endothelial 
cell proliferation and migration, which result in capillary 
sprouting or angiogenesis. The stimulation of PRP on 
angiogenesis is regulated by activation of PI3 kinase and 
extracellular signal-regulated kinase (ERK)8. However, 
neovascularization is a complex event, and interplay 
between cells and angiogenic factors ,not VEGF only, 
needed to form a stable capillary vessel9. The late issue is 
how to optimize the potency of growth factors contained 
in PRP. Bir et al, shown the efficacy of  sustained release 
of PRP in therapeutic neovascularization and this 
potentiation is triggered by stimulation of angiogenesis, 
arteriogenesis, and vasculogenesis in mouse hind limb 
ischemia 10. We will need more studies to improve the 
potency of PRP in proliferation and differentiation.
Conclusion
The results of this study define that PRP increases EPC 
proliferation from peripheral blood of SCAD patient 
compared to PPP and control group.
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